Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

US Supreme Court to hear Bayh-Dole patent ownership dispute: Stanford v Roche (Patently-O) (IPKat) (IPBiz)

US DoJ amicus brief in Myriad says no to patentability of genomic DNA: AMP v USPTO (IPBiz) (Inventive Step) (Patently-O) (Patent Docs) (Holman’s Biotech IP Blog)

Gemzar (Gemcitabine) – US: CAFC denies en banc rehearing of ‘distorted’ law of double-patenting: Sun Pharmaceuticals v Eli Lilly (Peter Zura’s 271 Patent Blog) (Patently-O)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Bell tolls for biodiversity benefit-sharing treaty (IP Watch)

Ministers arrive to help reach outcome at UN convention on biodiversity (IP Watch)

Delegates see UN protocol against biopiracy within reach (IP Watch)

Pfizer and Biocon sign global commercialisation agreement on biosimilars (Patent Docs)

Brazil: Paragraph 6 system: Brazilian intervention at the WTO TRIPS Council (KEI)

Canada’s intervention to TRIPS Council: Experience using the System (Apotex-Rwanda Case) (KEI)

China: Patent Law application on genetic resources (China Blawg)

EU: EPO TBA on automatic genotype determination in field of bioinformatics. Features pertaining to a general manner of analysing data are found to be ignored in assessing inventive step (EPLAW) (IPKat)

Hungary: Preliminary injunction not available if scope of protection defined in main claim is different from the one that can be derived based on the description (EPLAW)

India: Big pharma stranglehold: Thwarting India as independent maker of blockbuster HIV drugs? (IP Watch)

Netherlands: The Hague Court of Appeal defines ‘offer’ prior to patent expiry: GlaxoSmithKline v. Pharmachemie (EPLAW)

US: Supreme Court to hear Bayh-Dole patent ownership dispute: Stanford v Roche (Patently-O) (IPKat) (IPBiz)

US: DoJ amicus brief in Myriad says no to patentability of genomic DNA: AMP v USPTO (IPBiz) (Inventive Step) (Patently-O) (Patent Docs) (Holman’s Biotech IP Blog)

US: Briefing update: AMP v USPTO (Patent Docs)

US: BIO and AUTM file amicus brief in Myriad case (PatentlyBIOtech)

US: Myriad files appeal brief in AMP v USPTO (Patent Docs)

US: Is it patentable? No – discussion of patent-eligibility standards for genes (Patent Baristas)

US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs)

US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog)

US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog)

Products

Botox (Botulinum) – EU: General Court upholds opposition to BOTUMAX Community trademark: Farmeco v OHMI, Allergan (Class 46)

Crestor (Rosuvastatin) – US: AstraZeneca files complaint against Watson following Para IV certification (Patent Docs) (SmartBrief)

Crestor (Rosuvastatin) – US: Killed by own bullet: Teva v AstraZeneca (PatLit)

Edluar (Zolpidem) – US: Orexo files patent infringement complaint against Edict Pharmaceuticals following Para IV challenge (Patent Docs)

Exelon (Rivastigmine) – US: Novartis files complaints in Delaware and S D Florida against Apotex following Para IV certification filing (Patent Docs)

Fluvastatin – Belgium: Brussels court of appeal reverses commercial court’s rejection of Novartis claim for preliminary injunction: Novartis v Mylan (EPLAW)

Gemzar (Gemcitabine) – US: CAFC denies en banc rehearing of ‘distorted’ law of double-patenting: Sun Pharmaceuticals v Eli Lilly (Peter Zura’s 271 Patent Blog) (Patently-O)

Losec / Prilosec (Omeprazole) – US: CAFC denies Andrx mandamus petition in Omeprazole litigation: In re Andrx Pharmaceuticals, Inc (Orange Book Blog)

Paxil (Paroxetine) – US: 3^rd Circuit denies Mylan motion for interim injunction (SmartBrief)

Pulicort (Budesonide) – US: CAFC affirms preliminary injunction against Apotex’s generic version of Pulmicort Respules: AstraZeneca v Apotex (Orange Book Blog)

Seroquel (Quetiapine) – US: AstraZeneca files patent infringement complaint against Mylan in response to Para IV certification (Patent Docs)

Strattera (Atomoxetine) – US: Zydus seeks declaratory judgment that it may proceed with manufacture and sale of generic version of Eli Lilly’s Strattera based on finding of invalidity (Patent Docs)

Trusopt (Dorzolamide) – Netherlands: District Court of The Hague invalidates Dutch part of Merck’s European patent: Sandoz v Merck (EPLAW)

Viagra (Sildenafil) – Israel: Four suspected of importing fake Viagra into Israel remanded in custody (The IP Factor)

Zemplar (Paricalcitol) – US: Abbott files patent infringement complaint against Anchen in response to Para IV certification (Patent Docs)